Department of Bioengineering and Therapeutic Sciences

Navigating the Pipeline: Alum Drives Drug Development at Eli Lilly

Mon Jun 16, 2025
Muhammad Baluom portrait
Muhammad Baluom, PhD, an executive director of clinical pharmacology at Eli Lilly and Company, reflects on his journey from becoming a pharmacist in Jerusalem to pursuing postdoctoral studies in the lab of the legendary Leslie Benet, PhD, and to leading the clinical pharmacology programs behind...

Second Annual PSR Symposium Spotlights the Power of Collaboration

Tue Jun 10, 2025
Mahendra Wagle

Bhushan Kharbikar, PhD, with Su Guo, PhD, was one of four poster winners.

The school's second annual PSR Symposium brought together postdocs, specialists, and researchers for a day of scientific presentations, career discussion, and recognition hosted by the Center for Collaborative Innovation.

NSF and NIH Recognize Kortemme's Leadership in AI-Driven Protein Design

Wed May 28, 2025
Kortemme

Tanja Kortemme, PhD

The latest publication from the lab of Department of Bioengineering and Therapeutic Sciences professor and Vice Dean of Research Tanja Kortemme, PhD, along with a $1.4 million award from the National Science Foundation, recognizes major possibilities and support for her vision of integrating AI and...

James Fraser Honored with Carl Brändén Award from The Protein Society

Tue May 27, 2025
Fraser

James Fraser, PhD

The Department of Bioengineering and Therapeutic Sciences chair was honored for pioneering advances in room-temperature X-ray data collection techniques and ensemble modeling methods, which have enabled deeper understanding and engineering of proteins. He has also been a champion of collaborative,...

Could this Molecule be ‘Checkmate’ for Coronaviruses like SARS-CoV-2?

Thu Apr 24, 2025
Craik

Charles Craik, PhD

Powerful drug candidates perform better than Paxlovid against SARS-CoV-2 and could head off future coronavirus pandemics. The research, from a team at UCSF and Gladstone Institutes that includes School of Pharmacy researchers, has stalled since the grant was cut.

Bridging borders in science: Q&A with Einstein Visiting Fellow Nevan Krogan, PhD

Wed Apr 23, 2025
The Department of Bioengineering and Therapeutic Sciences professor will lead a new global research initiative with Freie Universität Berlin, establishing a Berlin-based lab to advancing cross-border collaboration and innovation in structural biology, infectious disease and therapeutic discovery.

Full Circle Symposium Brings Together Native and Indigenous Scientists

Fri Apr 11, 2025
Coyote-Maestas

Department of Bioengineering and Therapeutic Sciences Assistant Professor Willow Coyote-Maestas, PhD, MS

Led by Department of Bioengineering and Therapeutic Sciences Assistant Professor Willow Coyote-Maestas, PhD, MS, and presented by the school’s Quantitative Biosciences Institute (QBI), the symposium — which is open to all — aims to build a thriving community for Native and Indigenous scientists in...

Koda-Kimble Seed Award Fuels 11 Innovative Projects

Mon Mar 31, 2025
Eleven innovative projects with the potential to further the mission of the UCSF School of Pharmacy in new ways will garner a financial boost from the 2025 Mary Anne Koda-Kimble Seed Award for Innovation.

Kortemme awarded International Feodor Lynen Medal from the German Society for Biochemistry and Molecular Biology

Thu Mar 20, 2025
Kortemme

Tanja Kortemme, PhD

The school’s vice dean of research received the award at an annual event that fosters scientific exchange among experts in biochemistry and molecular biology, where she delivered a lecture that delved into her work on the creation of novel proteins and their applications in engineering molecular...

Decoding COVID-19: QBI Researchers Pave the Way for New Drug Discoveries to Combat Virus

Tue Mar 11, 2025
Krogan (left) in his lab with Xu (right)
Susan Merrell

Nevan Krogan, PhD, left, director of the Quantitative Biosciences Institute and founder of the UCSF Coronavirus Research Group, and Jiewei Xu, specialist in the department of Cellular & Molecular Pharmacology, worked around the clock mapping human proteins with the goal of finding a drugs to prevent COVID from replicating.

The QBI Coronavirus Research Group (QCRG) fast-tracked antiviral drug discovery by partnering with scientists around the globe and around the clock, deepening understanding of how viruses attack cells and shaping the future of pandemic preparedness.

Pages